[{"id":"1041c05e-29a6-455b-9723-ee6ca103e007","acronym":"","url":"https://clinicaltrials.gov/study/NCT04702841","created_at":"2021-01-19T20:50:56.628Z","updated_at":"2024-07-02T16:36:33.640Z","phase":"Phase 1","brief_title":"CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors","source_id_and_acronym":"NCT04702841","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UTAA07 • γδT Cell infusion • γδT Cell infusion agent"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/03/2020","start_date":" 06/03/2020","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-03-08"}]